In the era of prostate cancer screening, mortality rates have fallen 40 percent. The price of that has been over-diagnosis and over-treatment, something the current health care system cannot sustain. One of the major goals of Cooperberg’s research is to develop better risk assessment tools and instruments that can give the patient and doctor more confidence that the patient’s cancer will not progress.
Matthew Cooperberg, MD, MPH
UCSF Department of Urology
Funding for Cooperberg’s research is provided by the Department of Defense and the National Institutes of Health.